Sign In
Buy FBRX
$17.00
-1.18 (-6.46%)
At Close: Jun 03, 2026
Forte Biosciences Target of Unusually High Options Trading (NASDAQ:FBRX)
02:12am, Thursday, 27'th Nov 2025
Forte Biosciences, Inc. (NASDAQ: FBRX - Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock traders purchased 30,205 call options on the company. This represents an
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
04:01pm, Monday, 24'th Nov 2025
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclon
Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update
09:00am, Friday, 14'th Nov 2025
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced
Forte Biosciences, Inc. $FBRX Stake Boosted by AlphaQuest LLC
03:59am, Monday, 03'rd Nov 2025
AlphaQuest LLC grew its stake in shares of Forte Biosciences, Inc. (NASDAQ: FBRX) by 300.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission.
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
04:01pm, Friday, 03'rd Oct 2025
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced
Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium
09:00am, Monday, 15'th Sep 2025
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced additi
Forte Biosciences, Inc. Announces Results and Provides Update
04:01pm, Thursday, 14'th Aug 2025
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced
Forte Biosciences Announces Pricing of $75 Million Public Offering
12:28am, Wednesday, 25'th Jun 2025
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a publ
Forte Biosciences Announces Proposed Public Offering
04:01pm, Tuesday, 24'th Jun 2025
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study
07:18am, Monday, 23'rd Jun 2025
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced
All You Need to Know About Forte Biosciences (FBRX) Rating Upgrade to Buy
01:05pm, Thursday, 03'rd Apr 2025
Forte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Forte Biosciences (FBRX) Is a Great Choice for 'Trend' Investors, Here's Why
10:01am, Friday, 03'rd Jan 2025
Forte Biosciences (FBRX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed thro
Here's Why Momentum in Forte Biosciences (FBRX) Should Keep going
09:51am, Thursday, 28'th Nov 2024
Forte Biosciences (FBRX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed thro
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced
Forte Biosciences (FBRX) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Tuesday, 19'th Nov 2024
Forte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
